Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options
If you suffered losses in Jasper and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
On July 7, 2025, Jasper Therapeutics, Inc. announced updated data from its BEACON Study, revealing that results from certain dosing cohorts were compromised by issues with a specific drug product lot affecting 10 of 13 patients. The Company stated it was investigating the affected lot, ensuring its return, and providing alternative lots for continued dosing.
Jasper further disclosed that the same defective lot had been used in the ETESIAN Study, leading the Company to halt that study and pause development in asthma. Additionally, Jasper announced it was halting development in SCID and would implement cost-cutting measures, including a potential restructuring, to extend its cash runway, contradicting earlier assurances of financial stability through the third quarter of 2025.
Following the announcement, Jasper’s stock plunged $3.73, or 55.1%, closing at $3.04 per share on July 7, 2025.
To learn more about the Jasper Therapeutics, Inc. investigation, go to www.faruqilaw.com/JSPR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251106233549/en/
Contacts
Faruqi & Faruqi
Josh Wilson
877-247-4292 or 212-983-9330 (Ext. 1310)
